KIT and gastrointestinal stromal tumor: The current systemic treatment sequence in GIST based on regulatory approval guidelines [26] does not consider subtype of KIT mutations; however, emerging prospective data reveal that patient outcomes vary based on activity in distinct KIT mutation groups (KIT exon 9 vs. 11 and KIT exon 13/14 vs. 17/18).